Last reviewed · How we verify
Enstilar 0.005%-0.064% Topical Foam
Enstilar 0.005%-0.064% Topical Foam is a Corticosteroid + Vitamin D analog combination Small molecule drug developed by Psoriasis Treatment Center of Central New Jersey. It is currently FDA-approved for Plaque psoriasis in adults.
Enstilar combines a potent corticosteroid (betamethasone dipropionate) and a vitamin D analog (calcipotriene) to reduce inflammation and normalize skin cell differentiation in psoriasis.
Enstilar combines a potent corticosteroid (betamethasone dipropionate) and a vitamin D analog (calcipotriene) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis in adults.
At a glance
| Generic name | Enstilar 0.005%-0.064% Topical Foam |
|---|---|
| Sponsor | Psoriasis Treatment Center of Central New Jersey |
| Drug class | Corticosteroid + Vitamin D analog combination |
| Target | Glucocorticoid receptor; Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Betamethasone dipropionate is a Class III potent corticosteroid that suppresses inflammatory cytokines and immune cell infiltration in the skin. Calcipotriene is a vitamin D3 analog that promotes keratinocyte differentiation and reduces proliferation. Together, these agents provide complementary anti-inflammatory and anti-proliferative effects, delivered as a foam formulation for enhanced skin penetration and patient compliance.
Approved indications
- Plaque psoriasis in adults
Common side effects
- Application site irritation
- Skin atrophy
- Folliculitis
- Hypercalcemia (with systemic absorption)
Key clinical trials
- Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color (PHASE4)
- To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). (PHASE3)
- Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis (PHASE4)
- Enstilar in Combination With Biologic Agents (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enstilar 0.005%-0.064% Topical Foam CI brief — competitive landscape report
- Enstilar 0.005%-0.064% Topical Foam updates RSS · CI watch RSS
- Psoriasis Treatment Center of Central New Jersey portfolio CI
Frequently asked questions about Enstilar 0.005%-0.064% Topical Foam
What is Enstilar 0.005%-0.064% Topical Foam?
How does Enstilar 0.005%-0.064% Topical Foam work?
What is Enstilar 0.005%-0.064% Topical Foam used for?
Who makes Enstilar 0.005%-0.064% Topical Foam?
What drug class is Enstilar 0.005%-0.064% Topical Foam in?
What development phase is Enstilar 0.005%-0.064% Topical Foam in?
What are the side effects of Enstilar 0.005%-0.064% Topical Foam?
What does Enstilar 0.005%-0.064% Topical Foam target?
Related
- Drug class: All Corticosteroid + Vitamin D analog combination drugs
- Target: All drugs targeting Glucocorticoid receptor; Vitamin D receptor (VDR)
- Manufacturer: Psoriasis Treatment Center of Central New Jersey — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Plaque psoriasis in adults
- Compare: Enstilar 0.005%-0.064% Topical Foam vs similar drugs
- Pricing: Enstilar 0.005%-0.064% Topical Foam cost, discount & access